With the full-scale launch of its latest surgical robot set for the middle of this year, Intuitive said that, to date, the ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Flagship Pioneering is leveraging its year-old London outpost to forge new research collaborations across the pond. | ...

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. | The company’s cobas ...

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...

An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...